![Kevin Whelan on Twitter: "Interested to learn more about #IBD? Prof James Lindsay promotes use of the ECCO-e learning platform https://t.co/f6faP7NIRI #IBDdiet #ECCO… https://t.co/veMvbyI8WR" Kevin Whelan on Twitter: "Interested to learn more about #IBD? Prof James Lindsay promotes use of the ECCO-e learning platform https://t.co/f6faP7NIRI #IBDdiet #ECCO… https://t.co/veMvbyI8WR"](https://pbs.twimg.com/media/DLSH0K-XcAEd0CB.jpg:large)
Kevin Whelan on Twitter: "Interested to learn more about #IBD? Prof James Lindsay promotes use of the ECCO-e learning platform https://t.co/f6faP7NIRI #IBDdiet #ECCO… https://t.co/veMvbyI8WR"
![East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.](https://www.hirsla.lsh.is/bitstream/handle/2336/325171/Gut-2014-Burisch-588-97.pdf.jpg?sequence=6&isAllowed=y)
East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.
![PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients](https://i1.rgstatic.net/publication/330650184_P698_Persistence_clinical_effectiveness_and_safety_of_vedolizumab_in_the_post-marketing_real_clinical_practice_in_Italy_a_double-centre_2-year_experience_in_Crohn's_disease_and_ulcerative_colitis_pati/links/5e9f0a7692851c2f52b796be/largepreview.png)
PDF) P698 Persistence, clinical effectiveness and safety of vedolizumab in the post-marketing real clinical practice in Italy: a double-centre, 2-year experience in Crohn's disease and ulcerative colitis patients
![PDF) P775 Evolution of inflammatory bowel disease research from a bird's eye perspective: A text-mining analysis of publication trends and topics PDF) P775 Evolution of inflammatory bowel disease research from a bird's eye perspective: A text-mining analysis of publication trends and topics](https://i1.rgstatic.net/publication/338654911_P775_Evolution_of_inflammatory_bowel_disease_research_from_a_bird's_eye_perspective_A_text-mining_analysis_of_publication_trends_and_topics/links/5e4ab17ea6fdccd965aed04c/largepreview.png)
PDF) P775 Evolution of inflammatory bowel disease research from a bird's eye perspective: A text-mining analysis of publication trends and topics
European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Dis
![Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink](https://media.springernature.com/full/springer-static/image/art%3A10.1007%2Fs12325-019-00998-3/MediaObjects/12325_2019_998_Fig1_HTML.png)
Figure 1 | Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review | SpringerLink
P817 Live-vaccines and lactation in newborn exposed in utero to anti-TNF: A multi-centre French experience in inflammatory bowe
N029 Patients experience of advice received on the use of topical therapies in inflammatory bowel disease (IBD) N030 Real benefi
![PDF) P374 Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors PDF) P374 Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors](https://i1.rgstatic.net/publication/322894972_P374_Non-alcoholic_fatty_liver_disease_in_inflammatory_bowel_disease_Prevalence_and_risk_factors/links/5ac8d953a6fdcc8bfc823559/largepreview.png)